Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
~ AUROBINDO May 30,2022 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Sandra Kurla Complex, Sandra (E), Phiroz Jeejeebhoy Towers, MUMBAI ·400 051 25th floor, Dalal Street, MUMBAI ·400 001 Company Code No. AUROPHARMA
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q4FY22
Aurobindo Pharma Limited Earnings Presentation Q4FY22
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Index
Index Page Q4FY22 & FY22 Business & Financial Highlights 4 Financial Performance 11 Filings Snapshot 14 Aurobindo Pharma Limited | Earnings Presentation – Q4FY22 3
Slide 5: Q4FY22 & FY22 Business & Financial Highlights
Q4FY22 & FY22 Business & Financial Highlights 4
Slide 6: Consolidated Financial Performance (Excluding Natrol) – FY22
Consolidated Financial Performance (Excluding Natrol) – FY 22 Revenue (Rs Crore) EBITDA (Rs Crore) Profit After Tax 23,681 23,455 4,997 4,387 2,992 2,647 21.1% 18.7% FY21 FY22 FY21 FY22 FY21 FY22 EBITDA Margin *At the end of the quarter Aurobindo Pharma Limited | Earnings Presentation – Q4FY22 5
Slide 7: Consolidated Financial & Business Highlights (Excluding Natrol) – FY22
Consolidated Financial & Business Highlights (Excluding Natrol) – FY22 Revenue from operations at Rs 23,455 crore in FY22 Vs. Rs 23,681 crore Research & Development (R&D) spend at Rs 1,581 crore in FY22, 6.7% of revenue Vs. Rs 1,510 crore in FY21, 6.1% of revenue EBIDTA before Forex and Other income
Slide 8: Quarterly Performance (Excluding Natrol) – Q4 FY22
Quarterly Performance (Excluding Natrol) – Q4 FY22 Revenue (Rs Crore) US Revenue ($ Mn) 6,007 5,942 6,002 5,809 5,702 401 393 364 367 363 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q4FY22 EBITDA (Rs Crore) Net Debt to Equity* 1,276 1,209 1,187 0.00 -0.01 1,016 974 -0.04 -0.07 --0
Slide 9: Consolidated Financial & Business Highlights – Q4 FY22
Consolidated Financial & Business Highlights – Q4 FY22 Revenue from operations at Rs 5,809.4 crore, declined by 3.2% QoQ, US revenues at US$ 363.3 Million Research & Development (R&D) spend at Rs 431 crore in Q4FY22, 7.4% of revenue Vs. Rs. 393 crore in Q3FY22, 6.6% of revenue EBIDTA before Forex an
Slide 10: US Business Performance Highlights
US Business Performance Highlights Revenue (Rs Crore) Revenue mix – Q4FY22 Orals 2,856 2,728 67.2% 2,745 Total Injectables Injectables* 26.8% 19.3% Branded Q4FY21 Q3FY22 Q4FY22 Oncology** 7.5% OTC 6.1% US Formulations • US revenue in Q4FY22 decreased by 4.5% YoY to Rs. 2,728 crore and largely flat o
Slide 11: Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights
Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights In Rs Cr Europe Growth Markets ARV API 491 1,694 397 391 1,010 913 1,553 1,541 306 794 236 156 Q4FY21 Q3FY22 Q4FY22 Q4FY21 Q3FY22 Q4FY22 Q4FY21 Q3FY22 Q4FY22 Q4FY21 Q3FY22 Q4FY22 • Europe revenue in Q4FY22 was • Revenue from
Slide 12: Financial Performance
| _ Financial Performance ‘ AUROBINDO Committed to healthier life! 203 Windsor ‘Center Drive
Slide 13: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q4FY22 Q4FY21 (%) Chg Q3FY22 (%) Chg FY22 FY21 (%) Chg Revenue from operations 5,809.4 6,001.5 -3.2 6,002.2 -3.2 23,455.5 24,774.6 -5.3 Gross Profit 3,285.2 3,594.4 -8.6 3,258.0 0.8 13,315.2 14,872.2 -10.5 Gross Margin 56.5% 59.9% 54.3% 56.8%
Slide 14: Debt profile
Debt profile Debt as on (Rs Cr) Mar-19 Mar-20 Mar-21 Dec-21 Mar-22 Fx Loan US$ Mn Closing Rate1 US$ = INR 69.15 75.66 73.11 74.33 75.79 1007 732 674 592 313 Fx Loan restated in INR 6,959.0 5,549.2 4.928.8 3,711.1 2,222.7 248 Rupee Loan 8.1 16.9 43.6 1.2 150.1 57 180 Gross Debt 6,967.1 5,566.1 4,972.
Slide 15: Filing Status
§ AUROBINDO Committed to healthier life! 203 Windsor ‘Center Drive
Slide 16: US Filings Snapshot as on 31st March 2022
US Filings Snapshot as on 31st March 2022 ANDA Filings Addressable 505 Therapy ANDAs Market Size 386 (US$ Bn) Non - Injectables 119 CNS 134 27.80 Injectables 189 166 56 CVS 106 35.45 33 ARV** 41 1.06 Final Tentative Under Gastroenterological 37 3.54 Approved Awaiting final Approval Approval Review A
Slide 17: Global regulatory filing details
Global regulatory filing details As at As at As at As at As at As at As at As at Category Approvals Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Mar 22 Formulations US* 376 398 429 478 541 586 639 727 538 (FA: 505, TA:33) 2,902 Dossiers (346 Europe** 1,756 2,224 2,521 2,848 3,003 3,214 3,374 358
Slide 18: Thank You
Thank You For more information, contact Investor Relations | Corporate Communications +91 40 6672 5067 ir@aurobindo.com www.aurobindo.com